Synairgen PLC (AIM:SNG, OTC:SYGGF) has reaffirmed its dedication to the clinical development of its primary respiratory anti-viral asset, SNG001, as revealed in its first-half financial results, according to analysts at Cavendish.
The phase III SPRINTER trial and the United States Government's ACTIV-2 trial have yielded valuable data, suggesting that SNG001 could potentially mitigate the progression of respiratory diseases, particularly in high-risk and severely affected patients, the corporate broker noted.
As such, the company is actively identifying patients who are most likely to benefit from SNG001 to inform the design of future studies.
Additionally, Synairgen aims to extend its research to other vulnerable groups, including those suffering from viral pneumonia and immunocompromised individuals who struggle to combat respiratory viruses.
Financially, Synairgen is in a robust position with a net cash total of £14.6 million as of June 30, Cavendish.
This amount is expected to sustain the company's operations until the second half of 2024.
Mid-afternoon, the shares were off 11% at 7.56p.